Tocilizumab Effect on Lipid Profile in Correlation to Cardiovascular Events: A Retrospective Cohort Study

Table 6

Correlation between cholesterol and lipoprotein levels with tocilizumab dose, at different time points.

	3 months ()
Tocilizumab dose	CHOL	TRIG	LDL	HDL
Correlation coefficient^‡ ()	0.002	-0.28	-0.19	0.34
	6 months ()
Tocilizumab dose	CHOL	TRIG	LDL	HDL
Correlation coefficient^‡ ()	-0.05	0.08	-0.11	0.19
	12 months ()
Tocilizumab dose	CHOL	TRIG	LDL	HDL
Correlation coefficient^‡ ()	0.34	0.41	0.32	-0.04
	18 months ()
Tocilizumab dose	CHOL	TRIG	LDL	HDL
Correlation coefficient^‡ ()	-0.03	0.78	0.15	-0.27
	24 months ()
Tocilizumab dose	CHOL	TRIG	LDL	HDL
Correlation coefficient^‡ ()	-0.25	0.01	-0.36	0.14
	30 months ()
Tocilizumab dose	CHOL	TRIG	LDL	HDL
Correlation coefficient^‡ ()	-0.99	-0.56	-0.93	0.24
	36 months ()
Tocilizumab dose	CHOL	TRIG	LDL	HDL
Correlation coefficient^‡ ()	-0.30	-0.39	-0.33	0.28

^‡Controlled for age at diagnosis and baseline level of cholesterol or lipoproteins. Statistical significance at . Statistical significance at .